In This Section      
 

Search Results

Title:
A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Protocol Number:
NCTNA151216
Phase:
Phase III
Physician:
Patrick Forde
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Johns Hopkins Bayview Medical Center
Sibley Memorial Hospital
Purpose:
The purpose of this research study is to examine lung cancer patients’ surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes.
Eligibility:
Generally healthy adults with resectable non-small cell lung cancer may be eligible.
Treatment:
A portion of tumor tissue previously collected for clinical purposes will be submitted to the study's lab for consenting patients who meet eligibility requirements. The tumor tissue will be assessed for EGFR and/or ALK mutations. Based on the results, patients will be offered the opportunity to participate on a research study using investigational agents.
Population:
Adult
Last Update
03/05/2019 05:03 AM